FDA Approves Microbiome Therapeutic Vowst to Prevent Recurrence of C. difficile Infections in Adults
Seres Therapeutics and Nestlé Health Science celebrate the FDA's approval of Vowst, a first-of-its-kind orally administered microbiota-based therapeutic set to transform the lives of patients with ...
Introduction: Data on the risk of hepatocellular carcinoma (HCC) recurrence in a transplanted liver following direct‑acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection are sparse and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback